1. [1] Stange, E.F., Travis, S.P., Vermeire, S., Beglinger, C., Kupcinkas, L., Geboes, K., Barakauskiene, A., Villanacci, V., Von Herbay, A., Warren, B.F., Gasche, C., Tilg, H., Schreiber, S.W., Scholmerich, J., and Reinisch, W.: European Crohn’s and Colitis Organisation.: European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut, 55 Suppl. 1, i1–15, 2006.
2. [2] Van, Assche., Geboes, K., and Rutgeerts, P.: Medical therapy for Crohn’s disease strictures. Inflamm. Bowel Dis., 10, 55–60, 2004.
3. [3] Dieleman, L.A., Pena, A.S., Meuwissen, S.G., and van Rees, E.P.: Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl., 223, 99–104, 1997.
4. [4] Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411–415, 1988.
5. Endothelin is a potent mitogen for rat vascular smooth muscle cells